Journal
MOLECULAR CELL
Volume 42, Issue 1, Pages 36-49Publisher
CELL PRESS
DOI: 10.1016/j.molcel.2011.02.020
Keywords
-
Categories
Funding
- CR-UK [C10652/A10250]
- NIH [R01GM062281]
- Scottish Executive Chief Scientist Office (CSO)
- Think Pink Scotland
- Cancer Research UK [12481] Funding Source: researchfish
- Chief Scientist Office [CAF/06/24] Funding Source: researchfish
Ask authors/readers for more resources
Mutations in both RAS and the PTEN/PIK3CA/AKT signaling module are found in the same human tumors. PIK3CA and AKT are downstream effectors of RAS, and the selective advantage conferred by mutation of two genes in the same pathway is unclear. Based on a comparative molecular analysis, we show that activated PIK3CA/AKT is a weaker inducer of senescence than is activated RAS. Moreover, concurrent activation of RAS and PIK3CA/AKT impairs RAS-induced senescence. In vivo, bypass of RAS-induced senescence by activated PIK3CA/AKT correlates with accelerated tumorigenesis. Thus, not all oncogenes are equally potent inducers of senescence, and, paradoxically, a weak inducer of senescence (PIK3CA/AKT) can be dominant over a strong inducer of senescence (RAS). For tumor growth, one selective advantage of concurrent mutation of RAS and PTEN/PIK3CA/AKT is suppression of RAS-induced senescence. Evidence is presented that this new understanding can be exploited in rational development and targeted application of prosenescence cancer therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available